Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Durham, North Carolina

Cancer biologic therapy trials in Durham, NC

36 cancer biologic therapy studies are recruiting participants at sites in Durham as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Durham at a glance

  • 36 studies are recruiting at a site in Durham.
  • By phase: Phase 1 (3), Phase 1/2 (1), Phase 2 (11), Phase 2/3 (3), Phase 3 (18).
  • By sponsor: industry (15), government (11), university, hospital or other (10).
  • By research area: Lymphoma (14), Lung Cancer (13), Breast Cancer (4), Melanoma (3), Pancreatic Cancer (1), Prostate Cancer (1).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Durham

Basic details from each study's public record (the 30 most recently updated of 36). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Duke University Medical Center
    Registry record
    NCT05564377 · updated
  2. A Study of PHST001 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pheast Therapeutics
    Study site
    Duke Cancer Institute
    Registry record
    NCT06840886 · updated
  3. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Duke University Medical Center
    Registry record
    NCT06876714 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Durham, NC on ClinicalTrials.gov.

Lung cancer studies recruiting in Durham

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Duke University Medical Center · Durham VA Medical Center
    Registry record
    NCT06498635 · updated
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT06767514 · updated
  3. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Duke University Medical Center
    Registry record
    NCT07388524 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Duke University Medical Center
    Registry record
    NCT04267848 · updated
  5. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Durham VA Medical Center
    Registry record
    NCT06096844 · updated
  6. A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Duke Cancer Institute
    Registry record
    NCT06646276 · updated
  7. Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    CatalYm GmbH
    Study site
    Duke University Medical Center
    Registry record
    NCT07246863 · updated
  8. A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

    • Phase 3
    • All ages
    • All sexes
    Sponsor
    Pierre Fabre Medicament
    Study site
    Duke Cancer Institute (Adults and Pediatrics)
    Registry record
    NCT03394365 · updated
  9. Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    CatalYm GmbH
    Study site
    Duke University Medical Center
    Registry record
    NCT07098988 · updated
  10. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Durham VA Medical Center
    Registry record
    NCT06616584 · updated
  11. Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Duke University Medical Center
    Registry record
    NCT05624996 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Durham, NC on ClinicalTrials.gov.

Prostate cancer studies recruiting in Durham

  1. Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    Convergent Therapeutics
    Study site
    Duke University Medical Center
    Registry record
    NCT06549465 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Durham, NC on ClinicalTrials.gov.

Melanoma studies recruiting in Durham

  1. A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Duke University
    Study site
    Duke University Medical Center
    Registry record
    NCT05077137 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Durham, NC on ClinicalTrials.gov.

Lymphoma studies recruiting in Durham

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Duke University Medical Center
    Registry record
    NCT06317662 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Duke University Medical Center
    Registry record
    NCT06337318 · updated
  3. A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307)
    Registry record
    NCT07634471 · updated
  4. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Duke University Medical Center
    Registry record
    NCT04269902 · updated
  5. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Duke University Medical Center
    Registry record
    NCT04546399 · updated
  6. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Duke University Medical Center
    Registry record
    NCT05675410 · updated
  7. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    Duke Cancer Institute
    Registry record
    NCT07188558 · updated
  8. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Duke University Medical Center
    Registry record
    NCT05976763 · updated
  9. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Allogene Therapeutics
    Study site
    Duke Blood Cancer Center
    Registry record
    NCT06500273 · updated
  10. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Duke University Medical Center
    Registry record
    NCT06124157 · updated
  11. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Duke University Medical Center
    Registry record
    NCT05633615 · updated
  12. Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Duke University Medical Center
    Registry record
    NCT07220187 · updated
  13. Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    • Phase 3
    • From 365 days, up to 25 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Duke University Medical Center
    Registry record
    NCT03959085 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Durham, NC on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Durham

  1. A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT06885034 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Durham, NC on ClinicalTrials.gov.

Ask about studies near Durham

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call